Microsampling: considerations for its use in pharmaceutical drug discovery and development
N Spooner, KD Anderson, J Siple, ER Wickremsinhe… - Bioanalysis, 2019 - Taylor & Francis
There is growing interest in the implementation of microsampling approaches for the
quantitation of circulating concentrations of analytes in biological samples derived from …
quantitation of circulating concentrations of analytes in biological samples derived from …
Analytical and diagnostic aspects of carbohydrate deficient transferrin (CDT): a critical review over years 2007–2017
F Bortolotti, D Sorio, A Bertaso, F Tagliaro - Journal of pharmaceutical and …, 2018 - Elsevier
The need for investigating alcohol abuse by means of objective tools is worldwide accepted.
Among the currently available biomarkers of chronic alcohol abuse, carbohydrate-deficient …
Among the currently available biomarkers of chronic alcohol abuse, carbohydrate-deficient …
A core outcome set for neonatal opioid withdrawal syndrome
LE Kelly, F Shan, S MacVicar, E Czaplinksi… - …, 2020 - publications.aap.org
BACKGROUND: As rates of neonatal opioid withdrawal are increasing, the need for
research to evaluate new treatments is growing. Large heterogeneity exists in health …
research to evaluate new treatments is growing. Large heterogeneity exists in health …
[HTML][HTML] Dried blood spots in neonatal studies: A computational analysis for the role of the hematocrit effect
Dried blood spot (DBS) microsampling is extensively employed in newborn screening (NBS)
and neonatal studies. However, the impact of variable neonatal hematocrit (Ht) values on …
and neonatal studies. However, the impact of variable neonatal hematocrit (Ht) values on …
Drug metabolism in early infancy: opioids as an illustration
T Van Donge, P Mian, D Tibboel… - Expert opinion on …, 2018 - Taylor & Francis
Introduction: Drug dosing in infants frequently depends on body weight as a crude indicator
for maturation. Fentanyl (metabolized by Cytochrome P450 3A4) and morphine …
for maturation. Fentanyl (metabolized by Cytochrome P450 3A4) and morphine …
Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period
J Samardzic, K Allegaert, M Wilbaux… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: For safe and effective neonatal antibiotic therapy, knowledge of the
pharmacokinetic parameters of antibacterial agents in neonates is a prerequisite. Fast …
pharmacokinetic parameters of antibacterial agents in neonates is a prerequisite. Fast …
[HTML][HTML] Evaluating the Taste Masking Ability of Two Novel Dispersible Tablet Platforms Containing Zinc Sulfate and Paracetamol Reconstituted in a Breast Milk …
Milk is often used as a dispersion medium for medicines administration in young children but
its taste-masking ability is unknown. A human taste panel was conducted to assess the …
its taste-masking ability is unknown. A human taste panel was conducted to assess the …
[HTML][HTML] Antimicrobial dosing in neonates
A Kontou, K Sarafidis, E Roilides - Expert Review of Clinical …, 2017 - Taylor & Francis
Neonatal sepsis still remains a significant cause of morbidity and mortality, prolonged
hospitalization, and increased medical costs. Early-and late-onset sepsis often presents with …
hospitalization, and increased medical costs. Early-and late-onset sepsis often presents with …
Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation …
YM Khong, J Liu, J Cook, V Purohit, K Thompson… - European Journal of …, 2021 - Elsevier
A pediatric formulation workshop entitled “Pediatric Formulations: Challenges of Today and
Strategies for Tomorrow” was held to advance pediatric drug product development efforts in …
Strategies for Tomorrow” was held to advance pediatric drug product development efforts in …
[HTML][HTML] The stable isotope method for determining absolute bioavailability
AJ Atkinson - Translational and Clinical Pharmacology, 2017 - synapse.koreamed.org
The bioavailability of a drug is usually assessed in healthy subjects. However, it is
reasonable to expect that significant alterations in bioavailability may occur in actual patients …
reasonable to expect that significant alterations in bioavailability may occur in actual patients …